GET THE APP

Inner Banner image

Be a part of Webinar on Cell Therapy

Call for Abstract

Date

March 23, 2021 at 10:00 AM CST  
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar

Cell and gene therapies are a transformative new category of medicines whose full potential is only just beginning to emerge.

 Cell and gene therapies are different. They involve extracting cells, protein or genetic material (DNA) from the patient (or a donor), and altering them to provide a highly personalised therapy, which is re-injected into the patient. Cell and gene therapies may offer longer lasting effects than traditional medicines. They have the potential to address complex diseases, such as motor neurone disease, and many rare disorders for which there are no effective treatments. In their simplest form, these therapies work by replacing a faulty or missing gene that causes an inherited condition, such as sickle cell anaemia or cystic fibrosis. Cell therapy is targeted at many clinical indications in multiple organs and by several modes of cell delivery.

Gene therapy remains a fairly new and still experimental procedure for the treatment of disease. In addition stem cells are still a relatively new concept and remain a confusing and complicated technology that much of the public struggles to understand. The potential for stem cells to be used in gene therapies is however, a valid one that has important ramifications for treating a range of diseases, many of which currently have no cure.

Regenerative pharmaceuticals have the one of a kind capacity to repair , supplant and recover tissues and organs , influenced because of some harm , infection. These drugs are ability of restoring the usefulness of cells and tissues. These medications have wide appropriateness in treating degenerative scatters including dermatology, cardio vascular, neurodegenerative sicknesses.Cell treatment is the quickest developing fragment of regenerative drug. This undeveloped cell treatment is making up the biggest part of this business sector.

Cell therapy may be defined as the treatment or prevention of disease by administration of cells that have been selected, manipulated, or altered outside the body. Using this definition, we see that cell-based therapeutic products have been used in the clinic for nearly 90 years in the form of blood transfusions and 50 years in the form of bone marrow transplants.

CAR T-cell therapy is a form of immunotherapy that uses specially altered T cells ‘a part of the immune system’ to fight cancer. A sample of a patient's T cells are collected from the blood, and then modified to produce special structures called chimeric antigen receptors (CARs) on their surface.

The field of molecular biology studies macromolecules and the macromolecular mechanisms found in living things, such as the molecular nature of the gene and its mechanisms of gene replication, mutation, and expression. Given the fundamental importance of these macromolecular mechanisms throughout the history of molecular biology, a philosophical focus on the concept of a mechanism generates the clearest picture of molecular biology’s history, concepts, and case studies utilized by philosophers of science.

Researchers are using stem cells in two important ways to improve cardiac health. ... Second, stem cells offer ways to replace damaged heart tissue. Using cellular therapy, researchers hope to repair or replace heart tissue damaged by congestive heart failure and heart attacks

Tissue Engineering is the investigation of the development of new connective tissues, or organs, from cells and a collagenous platform to create a completely useful organ for implantation over into the contributor host. Effective improvements in the multidisciplinary field of tissue building have created a novel arrangement of tissue new parts and execution approaches. Investigative advances in biomaterials, foundational microorganisms, development and separation components, and biomimetic situations have made special chances to manufacture tissues in the research facility from blends of designed extracellular networks cells, and organically dynamic particles.

Immuno cell therapy has emerged as an exciting new approach to cancer treatment that is yielding unprecedented, durable responses for patients with an increasingly diverse array of cancer types. Much of the excitement has centered around checkpoint inhibitors, immuno therapeutics that release the “brakes” on the surface of immune cells called T cells, some of which are naturally capable of destroying cancer cells. Immunotherapy involves engineering patients’ own immune cells to recognize and attack their tumors. And although this approach, called adoptive cell transfer (ACT), has been restricted to small clinical trials so far, treatments using these engineered immune cells have generated some remarkable responses in patients with advanced cancer. .Adoptive T cell therapy for cancer is a form of transfusion therapy consisting of the infusion of various mature T cell subsets with the goal of eliminating a tumor and preventing its recurrence.

Adoptive cell therapy is a complex medical procedure that is customized for each patient. It begins with the extraction of T cells. In the laboratory, these T cells are either genetically modified to target tumor-specific antigens and then expanded or are expanded based on their natural tumor reactivity. Once enough T cells have been generated, they are infused back into the patient to help mediate tumor regression.

There are several different types of adoptive cell therapy. One approach utilizes tumor-infiltrating lymphocytes (TILs) that are isolated from a patient’s tumor, expanded in number in the laboratory, and infused back into the patient. A second approach is to engineer the T cells harvested from a patient to express a tumor antigen–specific T-cell receptor (TCR) so that the T cells can recognize and attack tumor cells that express such antigens.

Allogeneic Cell Therapy: In allogeneic cell therapy the donor is a different person to the recipient of the cells. In pharmaceutical manufacturing, the allogeneic methodology is promising because unmatched allogeneic therapies can form the basis of "off the shelf" products. There is research interest in attempting to develop such products to treat conditions including Crohn’s disease and a variety of vascular conditions.

Autologous Cell Therapy: In autologous cell therapy, cells are transplanted that are derived from the patient’s own tissues. Multiple clinical studies are ongoing that obtain stromal cells from bone-marrow, adipose tissue, or peripheral blood to be transplanted at sites of injury or stress; which is being actively explored. It could also involve the isolation of matured cells from diseased tissues, to be later re-implanted at the same or neighboring tissues; a strategy being assessed in clinical trials.

Xenogeneic Cell Therapy: In xenogeneic cell therapies, the recipient will receive cells from another species. For example, the transplantation of pig derived cells to humans. Currently, xenogeneic cell therapies primarily involve human cell transplantation into experimental animal models for assessment of efficacy and safety. However future advances could potentially enable xenogeneic strategies to humans as well.

Cell Transplantation: Cell transplantation is a procedure in which cells that can be induced to become pluripotent stem cells, are transferred to a site where the tissue is damaged or diseased. The transfer can occur within an individual, between individuals, or between species. Cells can be treated before implantation.

 There are countless indications for cell therapy which have very real promise in numerous fields. This could concern clinical fields such as neurodegenerative diseases (Parkinson's or Alzheimer's disease) or muscle degeneration (Duchenne muscular dystrophy) if researchers are able to produce large quantities of different neuron sub-types and skeletal muscle cells. Dare we also envisage the possibility of producing blood cells, including platelets, in unlimited quantities to cover hospital blood needs? All hypotheses are now on the table.

Abstracts enquiry

abstracts@meetingsint.com

Finance enquiry

finance@meetingsint.com

Contact Enquiry

contact@meetingsint.com

Sponsors / Advertising

sponsor@meetingsint.com

Meetings International Pte Ltd, 28 Maxwell Road, 03-05 Red Dot Traffic, Singapore, 069120.